TriPath/BD Agreement Targeted At Developing Tests For Cancer Risk
TriPath Imaging expects to market its first gene-based diagnostic test to determine the risk of metastic melanoma by year-end as part of an agreement with BD Corp.
TriPath Imaging expects to market its first gene-based diagnostic test to determine the risk of metastic melanoma by year-end as part of an agreement with BD Corp.